Viking Therapeutics Inc
NASDAQ:VKTX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.98
42.09
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
3.4B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
387B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Viking Therapeutics Inc
Glance View
Viking Therapeutics Inc. stands at the intriguing intersection of clinical innovation and strategic execution, carving a unique niche in the biotechnology landscape. Founded with a mission to develop novel, first-in-class or best-in-class therapies, Viking Therapeutics is primarily focused on the areas of metabolic and endocrine disorders. Through harnessing cutting-edge science, the company is developing a robust portfolio of drug candidates aimed at tackling some of the most challenging and widespread health conditions. Its flagship product candidates include VK2809 and VK0214, both of which are addressing significant unmet needs in the treatment of nonalcoholic steatohepatitis (NASH), hypercholesterolemia, and X-linked adrenoleukodystrophy (X-ALD), respectively. Viking Therapeutics operates by capitalizing on its expertise in gene transcription regulation, specifically targeting metabolic pathways to alter disease progression. The company's business model leans heavily on progression through clinical trial phases, with the ultimate goal of securing Food and Drug Administration (FDA) approvals that can later translate into profitable licensing agreements or partnerships with larger pharmaceutical companies. By advancing these therapies through the meticulous phases of drug development, Viking aims to monetize its investments in research and development by leveraging the lucrative nature of market approvals and commercial partnerships. Through this meticulous balancing act of innovation and strategic alliances, Viking Therapeutics encapsulates the dynamic and high-stakes world of biotech entrepreneurship.